Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update.

Visvanathan K, Fabian CJ, Bantug E, Brewster AM, Davidson NE, DeCensi A, Floyd JD, Garber JE, Hofstatter EW, Khan SA, Katapodi MC, Pruthi S, Raab R, Runowicz CD, Somerfield MR.

J Clin Oncol. 2019 Sep 3:JCO1901472. doi: 10.1200/JCO.19.01472. [Epub ahead of print]

PMID:
31479306
2.

Ovarian cancer statistics, 2018.

Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL.

CA Cancer J Clin. 2018 Jul;68(4):284-296. doi: 10.3322/caac.21456. Epub 2018 May 29.

3.

Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.

Chlebowski RT, Anderson GL, Sarto GE, Haque R, Runowicz CD, Aragaki AK, Thomson CA, Howard BV, Wactawski-Wende J, Chen C, Rohan TE, Simon MS, Reed SD, Manson JE.

J Natl Cancer Inst. 2015 Dec 14;108(3). pii: djv350. doi: 10.1093/jnci/djv350. Print 2016 Mar.

4.

American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.

Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, LaMonte SJ, Warner E, Lyman GH, Ganz PA.

J Clin Oncol. 2016 Feb 20;34(6):611-35. doi: 10.1200/JCO.2015.64.3809. Epub 2015 Dec 7. Review.

PMID:
26644543
5.

American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.

Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A, Marks LB, LaMonte SJ, Warner E, Lyman GH, Ganz PA.

CA Cancer J Clin. 2016 Jan-Feb;66(1):43-73. doi: 10.3322/caac.21319. Epub 2015 Dec 7. Review.

6.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA.

Mayo Clin Proc. 2015 Aug;90(8):996-1000. doi: 10.1016/j.mayocp.2015.06.001. Epub 2015 Jul 23. No abstract available.

7.

Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.

Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH; American Society of Clinical Oncology.

J Clin Oncol. 2012 May 1;30(13):1553-61. doi: 10.1200/JCO.2011.39.9436. Epub 2012 Apr 2. Review.

PMID:
22473167
8.

Chemotherapy in pregnancy.

Brewer M, Kueck A, Runowicz CD.

Clin Obstet Gynecol. 2011 Dec;54(4):602-18. doi: 10.1097/GRF.0b013e318236e9f9. Review.

PMID:
22031250
9.

Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).

Runowicz CD, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Ford LG, Vogel VG, Wolmark N.

Am J Obstet Gynecol. 2011 Dec;205(6):535.e1-5. doi: 10.1016/j.ajog.2011.06.067. Epub 2011 Jun 24.

10.

Prevalence and prognostic role of triple-negative breast cancer by race: a surveillance study.

Swede H, Gregorio DI, Tannenbaum SH, Brockmeyer JA, Ambrosone C, Wilson LL, Pensa MA, Gonsalves L, Stevens RG, Runowicz CD.

Clin Breast Cancer. 2011 Oct;11(5):332-41. doi: 10.1016/j.clbc.2011.04.004. Epub 2011 May 12.

11.

Multimodal therapy in the treatment of vaginal adenocarcinoma arising from endocervicosis.

Starbuck K, Garcia C, Wu Q, Runowicz CD.

Gynecol Oncol. 2011 Jan;120(1):158-9. doi: 10.1016/j.ygyno.2010.10.006. Epub 2010 Nov 5. No abstract available.

PMID:
21056460
12.

Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer.

Vergote I, Finkler NJ, Hall JB, Melnyk O, Edwards RP, Jones M, Keck JG, Meng L, Brown GL, Rankin EM, Burke JJ, Boccia RV, Runowicz CD, Rose PG.

Int J Gynecol Cancer. 2010 Jul;20(5):772-80.

PMID:
20973267
13.

Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.

Blank SV, Christos P, Curtin JP, Goldman N, Runowicz CD, Sparano JA, Liebes L, Chen HX, Muggia FM.

Gynecol Oncol. 2010 Dec;119(3):451-6. doi: 10.1016/j.ygyno.2010.08.008. Epub 2010 Sep 15.

14.

Challenges to National Cancer Institute-Supported Cooperative Group Clinical Trial Participation: An ASCO Survey of Cooperative Group Sites.

Baer AR, Kelly CA, Bruinooge SS, Runowicz CD, Blayney DW.

J Oncol Pract. 2010 May;6(3):114-7. doi: 10.1200/JOP.200028. Epub 2010 Apr 15.

15.

Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial: 5-year gynecological outcomes.

Goldstein SR, Neven P, Cummings S, Colgan T, Runowicz CD, Krpan D, Proulx J, Johnson M, Thompson D, Thompson J, Sriram U.

Menopause. 2011 Jan;18(1):17-22. doi: 10.1097/gme.0b013e3181e84bb4.

PMID:
20689465
16.

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project.

Cancer Prev Res (Phila). 2010 Jun;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076. Epub 2010 Apr 19.

17.

The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer.

Khalil I, Brewer MA, Neyarapally T, Runowicz CD.

Gynecol Oncol. 2010 Feb;116(2):282-5. doi: 10.1016/j.ygyno.2009.10.085. Review.

PMID:
19931138
18.

Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study.

Kuo DY, Blank SV, Christos PJ, Kim M, Caputo TA, Pothuri B, Hershman D, Goldman N, Ivy PS, Runowicz CD, Muggia F, Goldberg GL, Einstein MH.

Gynecol Oncol. 2010 Mar;116(3):442-6. doi: 10.1016/j.ygyno.2009.10.082. Epub 2009 Nov 20.

19.

Ovarian cancer screening and early detection.

Joyner AB, Runowicz CD.

Womens Health (Lond). 2009 Nov;5(6):693-9. doi: 10.2217/whe.09.65. Review.

PMID:
19863472
20.

The impact of the privacy rule on cancer research: variations in attitudes and application of regulatory standards.

Goss E, Link MP, Bruinooge SS, Lawrence TS, Tepper JE, Runowicz CD, Schilsky RL.

J Clin Oncol. 2009 Aug 20;27(24):4014-20. doi: 10.1200/JCO.2009.22.3289. Epub 2009 Jul 20.

PMID:
19620480
21.

Human papillomavirus testing for primary cervical cancer screening.

Runowicz CD, Garozzo S.

Curr Oncol Rep. 2008 Nov;10(6):533-7. Review.

PMID:
18928670
22.

Intraperitoneal chemotherapy in ovarian cancer: an update.

Runowicz CD.

Cancer J. 2008 Jan-Feb;14(1):7-9. doi: 10.1097/PPO.0b013e318163c2e0. Review.

PMID:
18303475
23.

A midpoint assessment of the American Cancer Society challenge goal to decrease cancer incidence by 25% between 1992 and 2015.

Sedjo RL, Byers T, Barrera E Jr, Cohen C, Fontham ET, Newman LA, Runowicz CD, Thorson AG, Thun MJ, Ward E, Wender RC, Eyre HJ; ACS Cancer Incidence & Mortality Ends Committee.

CA Cancer J Clin. 2007 Nov-Dec;57(6):326-40.

24.

Molecular screening for cervical cancer--time to give up Pap tests?

Runowicz CD.

N Engl J Med. 2007 Oct 18;357(16):1650-3. No abstract available.

PMID:
17942878
25.

Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III.

Einstein MH, Kadish AS, Burk RD, Kim MY, Wadler S, Streicher H, Goldberg GL, Runowicz CD.

Gynecol Oncol. 2007 Sep;106(3):453-60. Epub 2007 Jun 22.

26.

American cancer society guideline for the early detection of cervical neoplasia and cancer.

Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, Cohen C.

J Low Genit Tract Dis. 2003 Apr;7(2):67-86.

PMID:
17051049
27.

Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia.

Einstein MH, Studentsov YY, Ho GY, Fazzari M, Marks M, Kadish AS, Goldberg GL, Runowicz CD, Burk RD.

Int J Cancer. 2007 Jan 1;120(1):55-9.

28.

GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma.

Goldman NA, Katz EB, Glenn AS, Weldon RH, Jones JG, Lynch U, Fezzari MJ, Runowicz CD, Goldberg GL, Charron MJ.

Mod Pathol. 2006 Nov;19(11):1429-36. Epub 2006 Aug 4.

29.

Clarifying cancer mortality rates.

Runowicz CD.

Science. 2006 Jul 14;313(5784):171-2. No abstract available.

PMID:
16840682
30.

A midpoint assessment of the American Cancer Society challenge goal to halve the U.S. cancer mortality rates between the years 1990 and 2015.

Byers T, Barrera E, Fontham ET, Newman LA, Runowicz CD, Sener SF, Thun MJ, Winborn S, Wender RC; American Cancer Society Incidence and Mortality Ends Committee.

Cancer. 2006 Jul 15;107(2):396-405.

31.

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP).

JAMA. 2006 Jun 21;295(23):2727-41. Epub 2006 Jun 5. Erratum in: JAMA. 2006 Dec 27;296(24):2926. JAMA. 2007 Sep 5;298(9):973.

PMID:
16754727
32.

Investment in cancer control and research: a sure bet.

Runowicz CD.

CA Cancer J Clin. 2006 Jan-Feb;56(1):9-10. No abstract available.

33.

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.

J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62.

PMID:
16288118
34.

Cervical cancer screening.

Holcomb K, Runowicz CD.

Surg Oncol Clin N Am. 2005 Oct;14(4):777-97. Review.

PMID:
16226691
35.

Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium.

Yi-Shin Kuo D, Timmins P, Blank SV, Fields AL, Goldberg GL, Murgo A, Christos P, Wadler S, Runowicz CD.

Gynecol Oncol. 2006 Jan;100(1):160-5. Epub 2005 Sep 29.

PMID:
16198398
36.

Preserving fertility after cancer.

Simon B, Lee SJ, Partridge AH, Runowicz CD.

CA Cancer J Clin. 2005 Jul-Aug;55(4):211-28; quiz 263-4. Review.

37.

Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia.

Li Z, Qiao Y, Liu B, Laska EJ, Chakravarthi P, Kulko JM, Bona RD, Fang M, Hegde U, Moyo V, Tannenbaum SH, Ménoret A, Gaffney J, Glynn L, Runowicz CD, Srivastava PK.

Clin Cancer Res. 2005 Jun 15;11(12):4460-8.

38.

Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.

Chalas E, Costantino JP, Wickerham DL, Wolmark N, Lewis GC, Bergman C, Runowicz CD.

Am J Obstet Gynecol. 2005 Apr;192(4):1230-7; discussion 1237-9.

PMID:
15846210
39.

What is a dropped bladder, and how is it treated?

Runowicz CD.

Health News. 2004 Aug;10(8):16. No abstract available.

PMID:
15551471
41.

Treating abnormal uterine bleeding. Hysterectomy is not always necessary.

Runowicz CD.

Health News. 2004 Jun;10(6):3. No abstract available.

PMID:
15199894
42.
43.

Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.

Hochster H, Plimack ER, Runowicz CD, Speyer J, Wallach RC, Sorich J, Mandeli J, Wadler S, Wright J, Muggia FM.

J Clin Oncol. 2004 Jan 1;22(1):120-6.

PMID:
14701774
44.
45.
46.

Innovations in understanding the biology of cervical cancer.

Wolf JK, Franco EL, Arbeit JM, Shroyer KR, Wu TC, Runowicz CD, Tortolero-Luna G, Herrero R, Crum CP.

Cancer. 2003 Nov 1;98(9 Suppl):2064-9. Review.

47.

What's my risk of getting an inherited form of breast cancer?

Runowicz CD.

Health News. 2003 Jul;9(7):12. No abstract available.

PMID:
12838930
48.

Evaluation of low-dose intraperitoneal interferon-alpha for palliation of ascites in patients with non-ovarian gynecologic malignancies.

Khabele D, Runowicz CD, Fields AL, Anderson PS, Goldberg GL.

Gynecol Oncol. 2003 Jun;89(3):420-3.

PMID:
12798705
49.
50.

I've heard that lymphedema can develop after cancer treatment. What is lymphedema, and how is it treated?

Runowicz CD.

Health News. 2003 Mar;9(3):12. No abstract available.

PMID:
12703443

Supplemental Content

Loading ...
Support Center